IGM Biosciences Inc represents values of innovation, integrity, and dedication in the field of biotechnology. With a strong emphasis on developing transformative and personalized therapies, IGM Biosciences Inc aims to improve the lives of patients suffering from serious diseases. The company's corporate philosophy revolves around scientific excellence, collaboration with experts, and a patient-centric approach. By leveraging its proprietary antibody engineering technology, IGM Biosciences Inc strives to create novel therapeutics that address significant unmet medical needs. Their commitment to advancing scientific research and delivering effective treatments underscores their mission to make a positive impact on global healthcare.

IGM Biosciences Inc is primarily present in the United States.

IGM Biosciences Inc has achieved several significant milestones. Notably, the company successfully completed its initial public offering in March 2020, raising approximately $175 million. Furthermore, IGM Biosciences has made substantial progress in advancing its pipeline of IgM antibody-based therapeutics. They have initiated clinical trials for their lead product candidate, IGM-2323, designed to treat patients with solid and hematologic malignancies. Additionally, the company has established strategic partnerships with renowned academic institutions and biopharmaceutical companies to further their research and development efforts. These achievements highlight IGM Biosciences' commitment to developing innovative therapies and advancing the field of immunoglobulin M (IgM) antibodies.

IGM Biosciences Inc is a renowned biotechnology company based in Mountain View, California. Established in 2010, the company focuses on the development of innovative immunotherapies for the treatment of cancer and other diseases. With a strong emphasis on research and development, IGM Biosciences Inc utilizes its proprietary platform technology, called IgM antibody technology, to develop next-generation antibodies for targeted therapy. The company has successfully collaborated with various pharmaceutical and biotech companies to advance its therapeutic pipeline. IGM Biosciences Inc aims to revolutionize the field of immunotherapy with its cutting-edge scientific approach and commitment to improving patient outcomes.

The main competitors of IGM Biosciences Inc in the market include established biotechnology companies such as Amgen, Inc., Gilead Sciences, Inc., and Genentech. These companies have a strong presence in the biopharmaceutical industry and compete with IGM Biosciences in terms of developing novel antibody therapies, conducting clinical trials, and commercializing their products. By continually innovating and leveraging its unique antibody engineering platform, IGM Biosciences strives to differentiate itself from its competitors and address unmet medical needs.

IGM Biosciences Inc is primarily active in the biotechnology and pharmaceutical industries.

IGM Biosciences Inc is a biotechnology company that focuses on the development and discovery of engineered IgM antibodies for the treatment of various diseases. With its innovative business model, IGM Biosciences Inc aims to leverage its expertise in antibody engineering to bring novel treatments to patients. The company utilizes its proprietary IgM antibody technology platform to create next-generation therapeutics with enhanced therapeutic potential. IGM Biosciences Inc is committed to addressing unmet medical needs and advancing the field of antibody-based therapies through its research and development efforts.

مُعامل القيمة السوقية إلى الأرباح لـ IGM Biosciences هو ؜-٣٫٣١.

مُعامِل القيمة إلى المبيعات IGM Biosciences هو ١١٫٧١.

نقاط جودة AlleAktien لـ IGM Biosciences هي 3/10.

المتوقعة IGM Biosciences الإيرادات هي ٤٦٫٧٠ مليون. USD.

صافي الربح المتوقعة IGM Biosciences هو ؜-١٦٥٫٣٧ مليون. USD.

IGM Biosciences Inc. is a biotechnology company that develops innovative products for cancer immunotherapy. Its business model is based on researching, developing, and commercializing monoclonal antibodies targeted specifically at cancer cells. IGM Biosciences Inc. has developed an advanced antibody engineering process known as the Antibody Engineering Platform (ADAPTIR). This technology allows the company to develop antibodies that target cells more specifically and have a higher efficacy than conventional antibodies. IGM Biosciences Inc. works closely with its customers to develop customized antibodies tailored to their specific needs. The company also has its own product pipeline focused on developing antibodies for the treatment of various types of cancer. One of the key areas of IGM Biosciences Inc. is preclinical research and development. The company has an experienced team of scientists and researchers working on developing new antibodies and therapies. The company also invests significant resources in clinical research to ensure the safety and efficacy of its products. IGM Biosciences Inc. also offers a wide range of services, including antibody manufacturing, product formulation and testing, and bulk antibody delivery. The company works with a variety of customers, including pharmaceutical companies, biotechnology companies, and research institutions. Some of the products developed by IGM Biosciences Inc. include IGM-2323, an antibody targeted at CD20, a protein found on B cells. IGM-2323 has been developed for the treatment of non-Hodgkin lymphomas and other B-cell disorders. Another important product of IGM Biosciences Inc. is IGM-8444, an antibody that targets the death receptor 5 or DR5. DR5 is a protein that is overexpressed in many cancer cells, including those resistant to standard treatments. IGM-8444 has shown promising results in preclinical studies and could become an important component of cancer therapy in the future. IGM Biosciences Inc. is a company dedicated to developing customized antibodies to fight cancer. The company has a unique technology platform that allows it to develop highly specific and powerful antibodies. IGM Biosciences Inc. has an experienced team of scientists and researchers working on developing new antibodies and therapies to provide more effective treatment for cancer patients.

يوزع IGM Biosciences أرباحًا قدرها 0 USD من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ IGM Biosciences في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـIGM Biosciences هو US4495851085.

رمز WKN لـ IGM Biosciences هو A2PPQK.

الرمز المُختصر لـ IGM Biosciences هو IGMS.

خلال آخر 12 شهراً، دفعت IGM Biosciences توزيعات أرباح بقيمة . وهذا يعادل عائد توزيعات أرباح يقارب . ومن المتوقع أن تدفع IGM Biosciences خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 USD.

نسبة توزيعات الأرباح الحالية لـ IGM Biosciences هي .

IGM Biosciences يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

IGM Biosciences دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 USD. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

IGM Biosciences يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة 0 USD من IGM Biosciences المُعلن عنها في ٢٤‏/٨‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ٢٤‏/٨‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ٢٤‏/٨‏/٢٠٢٤.

في العام 2023، وزعت IGM Biosciences 0 USD كأرباح أسهم.

يتم توزيع أرباح IGM Biosciences بالعملة USD.